Work Package 3 – Anti-ageing and angiogenesis bioassays
To evaluate the extracts and pure molecule libraries (EXΤLIB and MOLLIB), on a complete set of molecular, cellular and in-vivo bioassays. The vast majority of these bioassays are already available through existing screening bio-platforms of the TASCMAR consortium.
The extract and compound libraries from WP2 will be provided to the WP3 partners in order to assess their pharmaceutical, cosmeceutical and nutraceutical potential. Chosen targets will relate to molecules known to interfere with the molecular/cellular processes of cellular senescence, in vivo ageing and/or angiogenesis.
Metabolomics analyses of the EXTLIB extracts will be carried out and the WP2 fractions and prioritised extracts will be screened for cytotoxic effects in human cell-based assays. Prioritised fractions will then be screened in cell-based assays for bioactivity in suppressing biomolecule damage, thereby promoting anti-ageing effects. Selected lead compounds will be extensively tested for anti-ageing activity and/or angiogenesis modulating effects and the most bioactive ‘hits’ will be tested for in vivo longevity increasing effects, using Drosophila flies as a testing platform. The TARMIC microorganisms and derived enzymes will be evaluated for their biocatalytic potential in degrading POP (Persistent Organic Pollutant) compounds.